|1.||Pettit, George R: 6 articles (12/2012 - 01/2003)|
|2.||Kiss, Robert: 5 articles (03/2013 - 09/2007)|
|3.||Lefranc, Florence: 5 articles (03/2013 - 09/2007)|
|4.||Melody, Noeleen: 5 articles (12/2012 - 01/2003)|
|5.||Mathieu, Véronique: 4 articles (03/2013 - 02/2009)|
|6.||Van Goietsenoven, Gwendoline: 3 articles (03/2013 - 07/2009)|
|7.||Berger, Walter: 3 articles (11/2010 - 02/2009)|
|8.||Knight, John C: 3 articles (01/2006 - 01/2003)|
|9.||Herald, Delbert L: 3 articles (01/2006 - 01/2003)|
|10.||Evidente, Antonio: 2 articles (03/2013 - 11/2010)|
02/26/2009 - "Data generated in the present study show that narciclasine displays potent antitumor effects in apoptosis-resistant as well as in apoptosis-sensitive cancer cells by impairing the organization of the actin cytoskeleton in cancer cells at concentrations that are not cytotoxic (IC(50) values of 30-90 nM). "
02/26/2009 - "Narciclasine (1) is a plant growth regulator that has been previously demonstrated to be proapoptotic to cancer cells at high concentrations (> or = 1 microM). "
09/01/2007 - "It is postulated that the high selectivity of narciclasine to cancer cells might be linked, at least in part, to this activation of the death receptor pathway. "
04/27/2012 - "Against a panel of murine and human cancer cell lines, 3-epipancratistatin (1b) led to cell growth inhibition (GI(50) 2.2-0.69 μg/mL) some 100× less than that found for pancratistatin (1a) and narciclasine (2), thereby revealing an important configurational requirement in 1a for strong cancer cell growth inhibition."
09/01/2007 - "The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts."
09/01/2007 - "Our study has shown that the Amaryllidaceae isocarbostyril narciclasine induces marked apoptosis-mediated cytotoxic effects in human cancer cells but not in normal fibroblasts by triggering the activation of the initiator caspases of the death receptor pathway (caspase-8 and caspase-10) at least in human MCF-7 breast and PC-3 prostate carcinoma cells. "
|4.||Melanoma (Melanoma, Malignant)
11/01/2010 - "eEF1A is thus a potential target to combat melanomas regardless of their apoptosis-sensitivity, and this finding reconciles the pleiotropic cytostatic of narciclasine. "
11/01/2010 - "Narciclasine displays IC(50) growth inhibitory values between 30-100 nM in melanoma cell lines, irrespective of their levels of resistance to proapoptotic stimuli. "
11/01/2010 - "At nontoxic doses, narciclasine also significantly improves (P=0.004) the survival of mice bearing metastatic apoptosis-resistant melanoma xenografts in their brain. "
03/01/2013 - "We have demonstrated that chronic treatments of narciclasine (1 mg/kg) significantly increased the survival of immunodeficient mice orthotopically xenografted with highly invasive human glioblastomas and apoptosis-resistant brain metastases, including melanoma- and non-small-cell-lung cancer- (NSCLC) related brain metastases. "
02/26/2009 - "However, one hemisynthetic derivative of narciclasine, compound 7k, demonstrated by both the intravenous and oral routes higher in vivo antitumor activity in human orthotopic glioma models in mice when compared to narciclasine at nontoxic doses. "
03/01/2013 - "At physiological doses, that is, approximately 50 nM in vitro and approximately 1 mg/kg in vivo, narciclasine is not cytotoxic but cytostatic and displays marked anticancer activity in vivo in experimental models of brain cancer (including gliomas and brain metastases), but it is not associated with toxic side effects. "
|7.||Leukocyte L1 Antigen Complex (Calgranulin)
|8.||Guanosine Triphosphate (GTP)
|1.||Heterologous Transplantation (Xenotransplantation)